There is reported evidence showing combined benefits from a PD1 antibody in combination with FAK inhibition against KRAS mutant cancer.[17] So, we strongly suspect that a triple combination of KRAS G12C, FAK, and PD1 inhibitors may provide further benefits to treatment outcomes against KRAS G12C mutant cancers. This evidence concerns the gene PTK2 and cancer.